Scalper1 News
Myriad Genetics (MYGN) was hit by multiple analyst downgrades Monday, and a 16% plunge on the stock market today, after the Center for Medicare & Medicaid Services confirmed over the weekend that it’s cutting reimbursement on Myriad’s genetic tests for breast-cancer vulnerability. Myriad was near 20.15 in morning trading Monday, a 52-week low. Late Friday, the CMS said that starting Jan. 1 it will pay $1,438.14 for Myriad’s test of the BRCA 1 and Scalper1 News
Scalper1 News